These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38482675)

  • 21. Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer.
    Genitsch V; Kollár A; Vandekerkhove G; Blarer J; Furrer M; Annala M; Herberts C; Pycha A; de Jong JJ; Liu Y; Krentel F; Davicioni E; Gibb EA; Kruithof-de Julio M; Wyatt AW; Seiler R
    Urol Oncol; 2019 Nov; 37(11):826-836. PubMed ID: 31585777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of programmed cell death ligand-1 expression in patients with bladder urothelial carcinoma undergoing radical cystectomy: A meta-analysis.
    Zhang J; Song L; Zhu H; Liu Q; Wang D
    Front Immunol; 2022; 13():986911. PubMed ID: 36248912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases.
    Davick JJ; Frierson HF; Smolkin M; Gru AA
    Hum Pathol; 2018 Nov; 81():184-191. PubMed ID: 29969606
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor expression of Nectin-1-4 and its clinical implication in muscle invasive bladder cancer: An intra-patient variability of Nectin-4 expression.
    Miyake M; Miyamoto T; Shimizu T; Ohnishi S; Fujii T; Nishimura N; Oda Y; Morizawa Y; Hori S; Gotoh D; Nakai Y; Torimoto K; Tanaka N; Fujimoto K
    Pathol Res Pract; 2022 Sep; 237():154072. PubMed ID: 35986963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sp1 is overexpressed and associated with progression and poor prognosis in bladder urothelial carcinoma patients.
    Zhu J; Lu Z; Ke M; Cai X
    Int Urol Nephrol; 2022 Jul; 54(7):1505-1512. PubMed ID: 35467245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Antibody-drug conjugates directed against NECTIN-4 as a new treatment option for patients with metastatic urothelial carcinoma].
    Klümper N; Eckstein M; Kunath F; Heidegger I; Becker C; Rausch S;
    Urologie; 2023 Nov; 62(11):1193-1199. PubMed ID: 37658236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trop-2 in Upper Tract Urothelial Carcinoma.
    Tomiyama E; Fujita K; Nakano K; Kuwahara K; Minami T; Kato T; Hatano K; Kawashima A; Uemura M; Takao T; Fushimi H; Katayama K; Imoto S; Yoshimura K; Imamura R; Uemura H; Nonomura N
    Curr Oncol; 2022 May; 29(6):3911-3921. PubMed ID: 35735421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemical Analysis of HER2, EGFR, and Nectin-4 Expression in Upper Urinary Tract Urothelial Carcinoma.
    Hashimoto M; Fujita K; Tomiyama E; Fujimoto S; Adomi S; Banno E; Minami T; Takao T; Nozawa M; Fushimi H; Yoshimura K; Nonomura N; Uemura H
    Anticancer Res; 2023 Jan; 43(1):167-174. PubMed ID: 36585180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Head-to-Head Comparison of the Expression Differences of NECTIN-4, TROP-2, and HER2 in Urothelial Carcinoma and Its Histologic Variants.
    Fan Y; Li Q; Shen Q; Liu Z; Zhang Z; Hu S; Yu W; He Z; He Q; Zhang Q
    Front Oncol; 2022; 12():858865. PubMed ID: 35515131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nectin-4 is widely expressed in head and neck squamous cell carcinoma.
    Sanders C; Lau JF; Dietrich D; Strieth S; Brossart P; Kristiansen G
    Oncotarget; 2022 Oct; 13():1166-1173. PubMed ID: 36268557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Precision Medicine in Urothelial Carcinoma: Current Markers to Guide Treatment and Promising Future Directions.
    Miller EJ; Galsky MD
    Curr Treat Options Oncol; 2023 Dec; 24(12):1870-1888. PubMed ID: 38085403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative differentiation of non-invasive bladder urothelial carcinoma and inverted papilloma based on CT urography.
    Jin P; Yang L; Liu Y; Huang J; Wang X
    BMC Urol; 2024 Mar; 24(1):73. PubMed ID: 38532363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PD-L1 testing in urothelial bladder cancer: essentials of clinical practice.
    Rouanne M; Radulescu C; Adam J; Allory Y
    World J Urol; 2021 May; 39(5):1345-1355. PubMed ID: 33141317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression and function analysis of indoleamine 2 and 3-dioxygenase in bladder urothelial carcinoma.
    Yang C; Zhou Y; Zhang L; Jin C; Li M; Ye L
    Int J Clin Exp Pathol; 2015; 8(2):1768-75. PubMed ID: 25973066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort.
    Nielsen TJ; Varga MG; Cronister CT; Ring BZ; Seitz RS; Ross DT; Schweitzer BL; McGregor K
    Cancer Immunol Immunother; 2023 Jul; 72(7):2075-2086. PubMed ID: 36806983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of transcription factor Twist1 in bladder urothelial carcinoma and its clinical significance.
    Tang X; Xing J; Li W; Wu Z; Zhang K; Zheng J
    J BUON; 2013; 18(1):211-9. PubMed ID: 23613408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Solute carrier family 12 member 5 promotes tumor invasion/metastasis of bladder urothelial carcinoma by enhancing NF-κB/MMP-7 signaling pathway.
    Liu JY; Dai YB; Li X; Cao K; Xie D; Tong ZT; Long Z; Xiao H; Chen MK; Ye YL; Liu B; Tan J; Tang J; Xu ZZ; Gan Y; Zhou YH; Deng F; He LY
    Cell Death Dis; 2017 Mar; 8(3):e2691. PubMed ID: 28333147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Invasive urothelial carcinoma exhibiting basal cell immunohistochemical markers: A variant of urothelial carcinoma associated with aggressive features.
    Mai KT; Truong LD; Ball CG; Williams P; Flood TA; Belanger EC
    Pathol Res Pract; 2015 Aug; 211(8):610-8. PubMed ID: 26100813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-L1 immunoexpression and molecular characterization of histological subtypes in urothelial carcinoma.
    Dawid de Vera MT; Prieto Cuadra JD; Álvarez Pérez M; Garrido-Aranda A; Alba Conejo E; Hierro Martín I
    Rev Esp Patol; 2023; 56(1):10-20. PubMed ID: 36599596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MAFG-AS1/MAFG positive feedback loop contributes to cisplatin resistance in bladder urothelial carcinoma through antagonistic ferroptosis.
    Xiang L; Zeng Q; Liu J; Xiao M; He D; Zhang Q; Xie D; Deng M; Zhu Y; Liu Y; Bo H; Liu X; Zhou M; Xiong W; Zhou Y; Zhou J; Li X; Cao K
    Sci Bull (Beijing); 2021 Sep; 66(17):1773-1788. PubMed ID: 36654385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.